CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Park, Sanghui | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Jang, Seung Jun | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.date.available | 2020-02-29T04:44:33Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2012-12 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/15959 | - |
dc.description.abstract | In order to evaluate prognostic value of CD99 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent treatment with rituximab-CHOP immunochemotherapy, immunohistochemistry for CD99/CD10/BCL-2/BCL-6/MUM-1 was performed on nodal DLBCL specimens from 70 patients. Patients were classified as either germinal center B-cell (GCB) subtype or non-GCB subtype according to the Muris algorithm. A superior 2-year event-free survival (EFS) was observed in patients with the GCB subgroup, compared to those with the non-GCB subgroup (p = 0.034). The distribution of CD99 expression (29 patients; 41.4 %) did not show deviation according to subtype and was not prognostic for survival in the entire patient population. Among patients with the GCB subgroup, better EFS and overall survival (OS) were observed in CD99+ patients, compared to CD99- patients. Conversely, among patients with the non-GCB subgroup, inferior EFS and OS were reported in CD99+ patients. Superior 2-year EFS (p = 0.004) and 2-year OS (p = 0.003) were observed in patients with GCB/CD99+ and non-GCB/CD99- compared to the others, and the combination classification was found to be an independent prognostic factor. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.subject | TISSUE MICROARRAY | - |
dc.subject | GERMINAL CENTER | - |
dc.subject | PROGNOSTIC IMPACT | - |
dc.subject | EWINGS-SARCOMA | - |
dc.subject | R-CHOP | - |
dc.subject | IMMUNOREACTIVITY | - |
dc.subject | CLASSIFICATION | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | DOXORUBICIN | - |
dc.subject | VALIDATION | - |
dc.title | CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000310952300009 | - |
dc.identifier.doi | 10.1007/s00277-012-1533-z | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.91, no.12, pp.1897 - 1906 | - |
dc.identifier.scopusid | 2-s2.0-84870996651 | - |
dc.citation.endPage | 1906 | - |
dc.citation.startPage | 1897 | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 91 | - |
dc.citation.number | 12 | - |
dc.contributor.affiliatedAuthor | Hong, Junshik | - |
dc.contributor.affiliatedAuthor | Park, Jinny | - |
dc.contributor.affiliatedAuthor | Jang, Seung Jun | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.contributor.affiliatedAuthor | Sym, Sun Jin | - |
dc.contributor.affiliatedAuthor | Cho, Eun Kyung | - |
dc.contributor.affiliatedAuthor | Shin, Dong Bok | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | CD99 | - |
dc.subject.keywordAuthor | Diffuse large B-cell lymphoma | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Immunohistochemistry | - |
dc.subject.keywordPlus | TISSUE MICROARRAY | - |
dc.subject.keywordPlus | GERMINAL CENTER | - |
dc.subject.keywordPlus | PROGNOSTIC IMPACT | - |
dc.subject.keywordPlus | EWINGS-SARCOMA | - |
dc.subject.keywordPlus | R-CHOP | - |
dc.subject.keywordPlus | IMMUNOREACTIVITY | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.